1
|
Kim JY, Mo H, Kim J, Kim JW, Nam Y, Rim YA, Ju JH. Mitigating Effect of Estrogen in Alzheimer’s Disease-Mimicking Cerebral Organoid. Front Neurosci 2022; 16:816174. [PMID: 35401074 PMCID: PMC8990972 DOI: 10.3389/fnins.2022.816174] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Accepted: 02/16/2022] [Indexed: 12/12/2022] Open
Abstract
Alzheimer’s disease (AD) is the most common condition in patients with dementia and affects a large population worldwide. The incidence of AD is expected to increase in future owing to the rapid expansion of the aged population globally. Researchers have shown that women are twice more likely to be affected by AD than men. This phenomenon has been attributed to the postmenopausal state, during which the level of estrogen declines significantly. Estrogen is known to alleviate neurotoxicity in the brain and protect neurons. While the effects of estrogen have been investigated in AD models, to our knowledge, they have not been investigated in a stem cell-based three-dimensional in vitro system. Here, we designed a new model for AD using induced pluripotent stem cells (iPSCs) in a three-dimensional, in vitro culture system. We used 5xFAD mice to confirm the potential of estrogen in alleviating the effects of AD pathogenesis. Next, we confirmed a similar trend in an AD model developed using iPSC-derived cerebral organoids, in which the key characteristics of AD were recapitulated. The findings emphasized the potential of estrogen as a treatment agent for AD and also showed the suitability of AD-recapitulating cerebral organoids as a reliable platform for disease modeling and drug screening.
Collapse
Affiliation(s)
| | - Hyunkyung Mo
- CiSTEM Laboratory, Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea, Seoul, South Korea
| | | | - Jang Woon Kim
- CiSTEM Laboratory, Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea, Seoul, South Korea
| | | | - Yeri Alice Rim
- CiSTEM Laboratory, Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea, Seoul, South Korea
| | - Ji Hyeon Ju
- CiSTEM Laboratory, Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea, Seoul, South Korea
- YiPSCELL, Inc., Seoul, South Korea
- Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea
- *Correspondence: Ji Hyeon Ju,
| |
Collapse
|
2
|
Das PK, Rakib MA, Khanam JA, Pillai S, Islam F. Novel Therapeutics Against Breast Cancer Stem Cells by Targeting Surface Markers and Signaling Pathways. Curr Stem Cell Res Ther 2019; 14:669-682. [DOI: 10.2174/1574888x14666190628104721] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2019] [Revised: 05/27/2019] [Accepted: 06/13/2019] [Indexed: 12/12/2022]
Abstract
Background:
Breast cancer remains to be one of the deadliest forms of cancers, owing to
the drug resistance and tumor relapse caused by breast cancer stem cells (BCSCs) despite notable advancements
in radio-chemotherapies.
Objective:
To find out novel therapeutics against breast cancer stem cells by aiming surface markers
and signaling pathways.
Methods:
A systematic literature search was conducted through various electronic databases including,
Pubmed, Scopus, Google scholar using the keywords "BCSCs, surface markers, signaling pathways
and therapeutic options against breast cancer stem cell. Articles selected for the purpose of this review
were reviewed and extensively analyzed.
Results:
Novel therapeutic strategies include targeting BCSCs surface markers and aberrantly activated
signaling pathways or targeting their components, which play critical roles in self-renewal and defense,
have been shown to be significantly effective against breast cancer. In this review, we represent a
number of ways against BCSCs surface markers and hyper-activated signaling pathways to target this
highly malicious entity of breast cancer more effectively in order to make a feasible and useful strategy
for successful breast cancer treatment. In addition, we discuss some characteristics of BCSCs in disease
progression and therapy resistance.
Conclusion:
BCSCs involved in cancer pathogenesis, therapy resistance and cancer recurrence. Thus,
it is suggested that a multi-dimensional therapeutic approach by targeting surface markers and aberrantly
activated signaling pathways of BCSCs alone or in combination with each other could really be
worthwhile in the treatment of breast cancer.
Collapse
Affiliation(s)
- Plabon K. Das
- Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi-6205, Bangladesh
| | - Md. A. Rakib
- Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi-6205, Bangladesh
| | - Jahan A. Khanam
- Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi-6205, Bangladesh
| | - Suja Pillai
- School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, Australia
| | - Farhadul Islam
- Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi-6205, Bangladesh
| |
Collapse
|